{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T05:59:40Z","timestamp":1783749580653,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological Psychiatry"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.biopsych.2016.10.012","type":"journal-article","created":{"date-parts":[[2016,10,18]],"date-time":"2016-10-18T17:15:43Z","timestamp":1476810943000},"page":"623-633","source":"Crossref","is-referenced-by-count":55,"title":["Trace Amine-Associated Receptor 1 Agonists as Narcolepsy Therapeutics"],"prefix":"10.1016","volume":"82","author":[{"given":"Sarah W.","family":"Black","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsui-Ming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius C.","family":"Hoener","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Kilduff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopsych.2016.10.012_bib1","doi-asserted-by":"crossref","first-page":"12305","DOI":"10.1523\/JNEUROSCI.2630-12.2012","article-title":"Narcolepsy: Neural mechanisms of sleepiness and cataplexy","volume":"32","author":"Burgess","year":"2012","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.10.012_bib2","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/79690","article-title":"A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains","volume":"6","author":"Peyron","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2016.10.012_bib3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/S0896-6273(00)00058-1","article-title":"Reduced number of hypocretin neurons in human narcolepsy","volume":"27","author":"Thannickal","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.10.012_bib4","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(99)05582-8","article-title":"Hypocretin (orexin) deficiency in human narcolepsy","volume":"355","author":"Nishino","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.biopsych.2016.10.012_bib5","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0014-4886(03)00388-1","article-title":"Relationship between CSF hypocretin levels and hypocretin neuronal loss","volume":"184","author":"Gerashchenko","year":"2003","journal-title":"Exp Neurol"},{"key":"10.1016\/j.biopsych.2016.10.012_bib6","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.neuroscience.2007.05.029","article-title":"The development of hypocretin (orexin) deficiency in hypocretin\/ataxin-3 transgenic rats","volume":"148","author":"Zhang","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2016.10.012_bib7","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0092-8674(00)81973-X","article-title":"Narcolepsy in orexin knockout mice: Molecular genetics of sleep regulation","volume":"98","author":"Chemelli","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.biopsych.2016.10.012_bib8","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/S0092-8674(00)81965-0","article-title":"The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene","volume":"98","author":"Lin","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.biopsych.2016.10.012_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0896-6273(03)00330-1","article-title":"Distinct narcolepsy syndromes in orexin receptor-2 and orexin null mice: Molecular genetic dissection of Non-REM and REM sleep regulatory processes","volume":"38","author":"Willie","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.10.012_bib10","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1523\/JNEUROSCI.5560-03.2004","article-title":"Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat","volume":"24","author":"Beuckmann","year":"2004","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.10.012_bib11","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0896-6273(01)00293-8","article-title":"Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity","volume":"30","author":"Hara","year":"2001","journal-title":"Neuron"},{"key":"10.1016\/j.biopsych.2016.10.012_bib12","doi-asserted-by":"crossref","first-page":"6495","DOI":"10.1523\/JNEUROSCI.0073-14.2014","article-title":"Conditional ablation of orexin\/hypocretin neurons: A new mouse model for the study of narcolepsy and orexin system function","volume":"34","author":"Tabuchi","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.10.012_bib13","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1093\/sleep\/33.10.1295","article-title":"Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy","volume":"33","author":"Burgess","year":"2010","journal-title":"Sleep"},{"key":"10.1016\/j.biopsych.2016.10.012_bib14","series-title":"Principles and Practice of Sleep Medicine","first-page":"957","article-title":"Narcolepsy: Diagnosis and management","author":"Guilleminault","year":"2011"},{"key":"10.1016\/j.biopsych.2016.10.012_bib15","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1523\/JNEUROSCI.21-05-01787.2001","article-title":"Dopaminergic role in stimulant-induced wakefulness","volume":"21","author":"Wisor","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.10.012_bib16","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/jpet.106.106583","article-title":"Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro","volume":"319","author":"Madras","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2016.10.012_bib17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0301-0082(96)00070-6","article-title":"Pharmacological aspects of human and canine narcolepsy","volume":"52","author":"Nishino","year":"1997","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.biopsych.2016.10.012_bib18","series-title":"Principles and Practice of Sleep Medicine","first-page":"938","article-title":"Narcolepsy: Pathophysiology and genetic predisposition","author":"Mignot","year":"2011"},{"key":"10.1016\/j.biopsych.2016.10.012_bib19","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0269881111421975","article-title":"Reconsidering GHB: orphan drug or new model antidepressant?","volume":"26","author":"Bosch","year":"2012","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.biopsych.2016.10.012_bib20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.smrv.2011.09.001","article-title":"Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials","volume":"16","author":"Boscolo-Berto","year":"2012","journal-title":"Sleep Med Rev"},{"key":"10.1016\/j.biopsych.2016.10.012_bib21","doi-asserted-by":"crossref","first-page":"8966","DOI":"10.1073\/pnas.151105198","article-title":"Trace amines: Identification of a family of mammalian G protein-coupled receptors","volume":"98","author":"Borowsky","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.10.012_bib22","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1124\/mol.60.6.1181","article-title":"Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor","volume":"60","author":"Bunzow","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2016.10.012_bib23","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity","volume":"324","author":"Lindemann","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.biopsych.2016.10.012_bib24","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1601-183X.2006.00292.x","article-title":"The trace amine 1 receptor knockout mouse: An animal model with relevance to schizophrenia","volume":"6","author":"Wolinsky","year":"2007","journal-title":"Genes Brain Behav"},{"key":"10.1016\/j.biopsych.2016.10.012_bib25","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1038\/npp.2012.109","article-title":"Brain-specific overexpression of trace amine-associated receptor 1 alters monoaminergic neurotransmission and decreases sensitivity to amphetamine","volume":"37","author":"Revel","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.10.012_bib26","doi-asserted-by":"crossref","first-page":"20081","DOI":"10.1073\/pnas.0906522106","article-title":"The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system","volume":"106","author":"Bradaia","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.10.012_bib27","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.biopsych.2016.10.012_bib28","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/npp.2015.65","article-title":"TAAR1 modulates cortical glutamate NMDA receptor function","volume":"40","author":"Espinoza","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.10.012_bib29","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pneurobio.2006.07.003","article-title":"The mysterious trace amines: Protean neuromodulators of synaptic transmission in mammalian brain","volume":"79","author":"Burchett","year":"2006","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.biopsych.2016.10.012_bib30","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.pharmthera.2007.06.007","article-title":"Trace amine-associated receptor 1\u2014family archetype or iconoclast?","volume":"116","author":"Grandy","year":"2007","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.biopsych.2016.10.012_bib31","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/nm1051","article-title":"3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone","volume":"10","author":"Scanlan","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2016.10.012_bib32","doi-asserted-by":"crossref","first-page":"E892","DOI":"10.1152\/ajpendo.00327.2004","article-title":"Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men","volume":"288","author":"Kok","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.biopsych.2016.10.012_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2174\/157488707779318107","article-title":"The potential of trace amines and their receptors for treating neurological and psychiatric diseases","volume":"2","author":"Berry","year":"2007","journal-title":"Rev Recent Clin Trials"},{"key":"10.1016\/j.biopsych.2016.10.012_bib34","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0021-9673(01)84617-3","article-title":"Biogenic amines and their metabolites in body fluids of normal, psychiatric and neurological subjects","volume":"466","author":"Davis","year":"1989","journal-title":"J Chromatogr"},{"key":"10.1016\/j.biopsych.2016.10.012_bib35","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1124\/mol.109.055970","article-title":"Trace amine-associated receptors as emerging therapeutic targets","volume":"76","author":"Sotnikova","year":"2009","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.biopsych.2016.10.012_bib36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.biopsych.2012.05.014","article-title":"Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics","volume":"72","author":"Revel","year":"2012","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.10.012_bib37","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.biopsych.2016.10.012_bib38","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/npp.2016.216","article-title":"Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition","volume":"42","author":"Schwartz","year":"2017","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopsych.2016.10.012_bib39","doi-asserted-by":"crossref","first-page":"379","DOI":"10.5665\/sleep.5448","article-title":"Quantitative EEG analysis provides an early-stage indicator of disease onset and progression in the zQ175 knock-in mouse model of Huntington\u2019s disease","volume":"39","author":"Fisher","year":"2016","journal-title":"Sleep"},{"key":"10.1016\/j.biopsych.2016.10.012_bib40","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1093\/brain\/awt132","article-title":"Longitudinal analysis of the sleep phenotype and EEG signatures in the R6\/2 model of Huntington\u2019s disease","volume":"136","author":"Fisher","year":"2013","journal-title":"Brain"},{"key":"10.1016\/j.biopsych.2016.10.012_bib41","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5665\/sleep.2442","article-title":"Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy","volume":"36","author":"Black","year":"2013","journal-title":"Sleep"},{"key":"10.1016\/j.biopsych.2016.10.012_bib42","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1523\/JNEUROSCI.0080-14.2014","article-title":"GABAB agonism promotes sleep and reduces cataplexy in murine narcolepsy","volume":"34","author":"Black","year":"2014","journal-title":"J Neurosci"},{"key":"10.1016\/j.biopsych.2016.10.012_bib43","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.biopsych.2016.10.012_bib44","unstructured":"Weller T, Koberstein R, Aissaoui H, Clozel M, Fischli W, inventors; Actelion Pharm, LTD, asignee. Substituted 1,2,3,4-tetrahydroisoquinoline derivatives. WIPO application WO 2005118548. December 15, 2005."},{"key":"10.1016\/j.biopsych.2016.10.012_bib45","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.neuroscience.2004.10.005","article-title":"Modafinil more effectively induces wakefulness in orexin-null mice than in wild-type littermates","volume":"130","author":"Willie","year":"2005","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopsych.2016.10.012_bib46","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pneurobio.2015.12.002","article-title":"Challenges in the development of therapeutics for narcolepsy","volume":"152","author":"Black","year":"2017","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.biopsych.2016.10.012_bib47","doi-asserted-by":"crossref","first-page":"111","DOI":"10.5665\/sleep\/32.1.111","article-title":"A consensus definition of cataplexy in mouse models of narcolepsy","volume":"32","author":"Scammell","year":"2009","journal-title":"Sleep"},{"key":"10.1016\/j.biopsych.2016.10.012_bib48","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1172\/JCI71017","article-title":"Orexin neurons suppress narcolepsy via 2 distinct efferent pathways","volume":"124","author":"Hasegawa","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.biopsych.2016.10.012_bib49","doi-asserted-by":"crossref","first-page":"7931","DOI":"10.1021\/acs.jmedchem.5b00988","article-title":"Design and synthesis of non-peptide, selective orexin receptor 2 agonists","volume":"58","author":"Nagahara","year":"2015","journal-title":"J Med Chem"}],"container-title":["Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316329213?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006322316329213?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T18:25:33Z","timestamp":1537295133000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006322316329213"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0006322316329213"],"URL":"https:\/\/doi.org\/10.1016\/j.biopsych.2016.10.012","relation":{},"ISSN":["0006-3223"],"issn-type":[{"value":"0006-3223","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]}}}